Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: A longitudinal controlled trial of combination therapy
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: A longitudinal controlled trial of combination therapy(561 views) Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V
Mult Scler (ISSN: 1352-4585, 1477-0970, 1352-4585linking), 2010 Apr; 16(4): 450-454.
Keywords: Activity, Combination Therapy, Interferon Beta, Multiple Sclerosis, Statin, Atorvastatin, Beta1a Interferon, Gadolinium, Antiinflammatory Agent, Beta Interferon, Contrast Medium, Diagnostic Agent, Heptanoic Acid Derivative, Pyrrole Derivative, Add On Therapy, Adult, Article, Blood Analysis, Cholesterol Blood Level, Clinical Article, Clinical Assessment, Clinical Trial, Contrast Enhancement, Controlled Clinical Trial, Controlled Study, Creatine Kinase Blood Level, Disease Course, Drug Efficacy, Drug Megadose, Drug Safety, Drug Tolerability, Expanded Disability Status Scale, Female, Human, Longitudinal Study, Low Drug Dose, Monotherapy, Muscle Cramp, Myalgia, Neuroimaging, Nuclear Magnetic Resonance Imaging, Outcome Assessment, Randomization, Randomized Controlled Trial, Relapse, Risk Assessment, Screening, Side Effect, Survival, Treatment Duration, Treatment Response, Chi Square Distribution, Drug Administration, Drug Combination, Hospitalization, Nonparametric Test, Prediction And Forecasting, Treatment Outcome, Anti-Inflammatory Agents, Chi-Square Distribution, Disability Evaluation, Drug Administration Schedule, Drug Therapy, Interferon-Beta, Longitudinal Studies, Relapsing-Remitting, Predictive Value Of Tests, Severity Of Illness Index, Statistics, Time Factors, Anti-Inflammatory Agents Administration, Dosage Adverse Effects Therapeutic Use, Contrast Media Diagnostic Use, Heptanoic Acids Administration, Interferon-Beta Administration, Relapsing-Remitting Diagnosis Drug Therapy, Pyrroles Administration,
Affiliations: *** IBB - CNR ***
Federico II University, Neurological Sciences Department, Naples, Italy
Hermitage Capodimonte, IDC, Naples, Italy
Biostructure and Bioimaging Institute, National Research Council, Naples, Italy
SDN, Foundation, Naples, Italy
Ospedale Moscati, Avellino, Italy
Second University of Naples, Neurology Department, Italy
Federico University, Neurological Sciences Department, Naples, Italy. robertalanzillo@libero.it
References: Baum, H., Rothschild, B., The incidence and prevalence of reported multiple sclerosis (1981) Ann. Neurol., 10, pp. 420-42
Weinshenker, B.G., Bass, B., Rice, G.P.A., Noseworthy, J., Carriere, W., Baskerville, J., Ebers, G.C., The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability (1989) Brain, 112 (1), pp. 133-146
Aktas, O., Waiczies, S., Smorodchenko, A., Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin (2003) J. Exp. Med., 197, pp. 725-733
Youssef, S., Stuve, O., Patarroyo, J.C., The HMGCoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease (2002) Nature, 420, pp. 78-84
Vollmer, T., Key, L., Durkalski, V., Tyor, W., Corboy, J., Markovic-Plese, S., Preiningerova, J., Singh, I., Oral simvastatin treatment in relapsing-remitting multiple sclerosis (2004) Lancet, 363 (9421), pp. 1607-1608. , DOI 10.1016/S0140-6736(04)16205-3, PII S0140673604162053
Birnbaum, G., Cree, B., Altafullah, I., Zinser, M., Reder, A.T., Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis (2008) Neurology, 71, pp. 1390-1395
Rudick, R.A., Pace, A., Rani, M.R., Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a (2009) Neurology, 72, pp. 1989-1993
McDonald, W.I., Compston, A., Edan, G., Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis (2001) Ann. Neurol., 50, pp. 121-127
Neuhaus, O., Strasser-Fuchs, S., Fazekas, F., Statins as immunomodulators (2002) Neurology, 59, pp. 990-997
Miron, V., Zehntner, S.P., Kuhlman, T., Statin therapy inhibits remyelination in the central nervous system (2009) Am. J. Pathol., 174, pp. 1880-1890
Sorensen, P.S., Frederiksen, J.L., Lycke, L., Does simvastatin antagonise the effect of interferon beta? Interim safety analysis of ongoing SIMCOMBIN study (2007) ECTRIMS, pp. 11-14. , October 2007, Prague, Czech Republic. Abstract 85
Martinez-Yelamos, S., Martinez-Yelamos, A., Martin Ozaeta, G., Regression to the mean in multiple sclerosis (2006) Mult Scler, 12, pp. 826-829
Weinshenker, B. G., Bass, B., Rice, G. P. A., Noseworthy, J., Carriere, W., Baskerville, J., Ebers, G. C., The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability (1989) Brain, 112 (1), pp. 133-146
Rudick, R. A., Pace, A., Rani, M. R., Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a (2009) Neurology, 72, pp. 1989-1993
McDonald, W. I., Compston, A., Edan, G., Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis (2001) Ann. Neurol., 50, pp. 121-127
Sorensen, P. S., Frederiksen, J. L., Lycke, L., Does simvastatin antagonise the effect of interferon beta? Interim safety analysis of ongoing SIMCOMBIN study (2007) ECTRIMS, pp. 11-14. , October 2007, Prague, Czech Republic. Abstract 85
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: A longitudinal controlled trial of combination therapy
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: A longitudinal controlled trial of combination therapy
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: A longitudinal controlled trial of combination therapy